期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 10, 期 5, 页码 711-728出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.29
关键词
amyloid-beta; beta-secretase; gamma-secretase; Alzheimer's disease; dementia; immunotherapy; tau; therapeutic; treatment
资金
- Elan
- Janssen
- Bristol-Myers Squibb
- Medivation
- Pfizer
- Alzheimer's Disease Cooperative Study (ADCS)
- NATIONAL INSTITUTE ON AGING [P50AG016570] Funding Source: NIH RePORTER
Alzheimer's disease is a progressive neurodegenerative disease for which no cure exists. There is a substantial need for new therapies that offer improved symptomatic benefit and disease-slowing capabilities. In recent decades there has been substantial progress in understanding the molecular and cellular changes associated with Alzheimer's disease pathology. This has resulted in identification of a large number of new drug targets. These targets include, but are not limited to, therapies that aim to prevent production of or remove the amyloid-beta protein that accumulates in neuritic plaques; to prevent the hyperphosphorylation and aggregation into paired helical filaments of the microtubule-associated protein tau; and to keep neurons alive and functioning normally in the face of these pathologic challenges. We provide a review of these targets for drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据